Rezolute(RZLT) - 2025 Q3 - Quarterly Results

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism Exhibit 99.1 REDWOOD CITY, Calif., May 13, 2025 -- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. Rezolute Reports Third Quarter Fiscal 2025 Financial Re ...